Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $6,826,755 | $6,965,719 | $7,053,206 | $6,602,510 |
| - Cash | $681,486 | $350,008 | $385,113 | $494,126 |
| + Debt | $4,645,320 | $4,505,942 | $4,515,265 | $4,840,148 |
| Enterprise Value | $10,790,589 | $11,121,653 | $11,183,358 | $10,948,532 |
| Revenue | $1,112,796 | $1,106,685 | $1,053,400 | $1,144,124 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Gross Profit | $732,735 | $722,010 | $671,300 | $727,250 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| EBITDA | $316,467 | $439,424 | $181,269 | $193,007 |
| % Margin | 28.4% | 39.7% | 17.2% | 16.9% |
| Net Income | -$11,802 | $124,243 | -$103,200 | $23,789 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS Diluted | -3.74 | 39.12 | -32.62 | 7.51 |
| % Growth | -109.6% | 219.9% | -534.4% | – |
| Operating Cash Flow | $378,228 | $215,423 | $222,159 | $383,756 |
| Capital Expenditures | -$52,825 | -$75,068 | -$48,793 | -$45,088 |
| Free Cash Flow | $325,403 | $140,355 | $173,366 | $338,668 |